$-0.77
(Market cap
$3,801 Mln
Recently Viewed
Clear AllMarket cap
$3,801 Mln
Revenue (TTM)
$62 Mln
P/E Ratio
--
P/B Ratio
11
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.4 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-0.9
Debt to Equity
0.1
Book Value
$3
EPS
$-0.9
Face value
--
Shares outstanding
142,688,851
CFO
$-241.32 Mln
EBITDA
$-344.52 Mln
Net Profit
$-334.11 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Tango Therapeutics Inc (TNGX)
| 183.3 | 32.4 | 114.3 | 1,607.5 | 90.9 | 17.1 | -- |
|
BSE Sensex
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Tango Therapeutics Inc (TNGX)
| 186.7 | -68.5 | 36.6 | -33.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Tango Therapeutics Inc (TNGX)
|
25.1 | 3,801.2 | 62.4 | -101.6 | -172.1 | -37.2 | -- | 11.0 |
| 74.9 | 9,733.6 | 1,091.0 | 202.3 | 31.6 | 31.3 | 43.4 | 17.1 | |
| 65.4 | 8,216.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 45.1 | 11,658.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.1 | 5.3 | |
| 89.4 | 11,852.6 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 65.4 | 8,209.1 | 1,396.6 | 316.9 | 59.8 | 153.6 | 27.1 | 161.7 | |
| 520.8 | 12,204.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.3 | |
| 415.6 | 14,867.3 | 2,530.2 | 451.1 | 21.3 | 70.2 | 34 | 32.4 | |
| 107.2 | 8,460.0 | 0.0 | -425.4 | -- | -36.7 | -- | 6.8 | |
| 339.3 | 9,538.9 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase... 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts. Read more
President, CEO & Director
Dr. Barbara L. Weber M.D.
President, CEO & Director
Dr. Barbara L. Weber M.D.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Tango Therapeutics Inc (TNGX) is $25.10 (NASDAQ) as of 24-Apr-2026 13:35 EDT. Tango Therapeutics Inc (TNGX) has given a return of 90.86% in the last 3 years.
Since, TTM earnings of Tango Therapeutics Inc (TNGX) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-10.12
|
2.97
|
|
2024
|
-2.58
|
1.69
|
|
2023
|
-9.24
|
3.72
|
|
2022
|
-5.90
|
2.56
|
|
2021
|
-11.65
|
1.97
|
The 52-week high and low of Tango Therapeutics Inc (TNGX) are Rs 28.41 and Rs 1.04 as of 25-Apr-2026.
Tango Therapeutics Inc (TNGX) has a market capitalisation of $ 3,801 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Tango Therapeutics Inc (TNGX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.